Evidence map›Paper›PMID 31391233›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2019

IL-33 Is a Cell-Intrinsic Regulator of Fitness during Early B Cell Development.

Matthew T Stier, Ramkrishna Mitra, Lindsay E Nyhoff, Kasia Goleniewska, Jian Zhang, Matthew V Puccetti, Holly C Casanova, Adam C Seegmiller, Dawn C Newcomb, Peggy L Kendall and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. B cells and food allergy.Current opinion in pediatrics · 2021
    Review
  14. IL-33 genetics and epigenetics in immune-related diseases.Clinical and molecular allergy : CMA · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Matthew T StierDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Ramkrishna MitraDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107; and.ORCID 0000-0002-6181-9066
Lindsay E NyhoffDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Kasia GoleniewskaDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232.
Jian ZhangDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232.
Matthew V PuccettiDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Holly C CasanovaDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Adam C SeegmillerDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Dawn C NewcombDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Peggy L KendallDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Christine M EischenDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107; and christine.eischen@jefferson.edu stokes.peebles@vanderbilt.edu.
R Stokes PeeblesDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232; christine.eischen@jefferson.edu stokes.peebles@vanderbilt.edu.ORCID 0000-0002-1429-7875
Vanderbilt University Medical Center · USThomas Jefferson University · US

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Viral and Host Determinants of Infant and Childhood Allergy and AsthmaU19AI095227 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Tina V Hartert · 2011 to 2026
$34.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Role of Gender in TH17-Mediated Inflammation in Severe AsthmaR01HL122554 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NEWCOMB, DAWN C · 2015 to 2024
$5.5M
Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 DiabetesR01DK084246 · NIDDK · WASHINGTON UNIVERSITY · PI KENDALL, PEGGY L · 2011 to 2019
$3.2M
PGI2 augments Treg functionR01AI145265 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2019 to 2023
$2.7M
GLP-1R signaling in allergic inflammationR01AI124456 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NISWENDER, KEVIN D, PEEBLES, RAY STOKES · 2017 to 2021
$2.2M
Replication stress in hematopoiesis and lymphomagenesisR01CA226432 · NCI · THOMAS JEFFERSON UNIVERSITY · PI EISCHEN, CHRISTINE M. · 2019 to 2023
$2.1M
PGI2 regulation of TSLP-mediated allergic inflammation in the lungR01AI111820 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2014 to 2018
$2.0M
Host genetics of allergen-induced lung TSLP expression and ILC2 functionR21AI145397 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2019 to 2020
$468k
UPGRADE OF X-RAY DIFFRACTOMETERS: PROTEIN &RNA RESEARCHS10RR020957 · NCRR · YALE UNIVERSITY · PI MOORE, PETER B. · 2005 to 2005
$344k
The Role of Group 2 Innate Lymphoid Cells in RSV-Induced Airway DysfunctionF30AI114262 · NIAID · VANDERBILT UNIVERSITY · PI STIER, MATTHEW T. · 2014 to 2017
$131k
BLRD VA I01 BX002882BLRD VA I01 BX004299NCATS NIH HHS UL1 TR000445NCI NIH HHS R01 CA226432NCRR NIH HHS S10 RR020957NHLBI NIH HHS R01 HL122554NIAID NIH HHS F30 AI114262NIAID NIH HHS R01 AI111820NIAID NIH HHS R01 AI124456NIAID NIH HHS R01 AI145265NIAID NIH HHS R21 AI145397NIAID NIH HHS U19 AI095227NIDDK NIH HHS R01 DK084246NIGMS NIH HHS T32 GM007347
6 · The paper itself

Abstract

IL-33 is an IL-1 family member protein that is a potent driver of inflammatory responses in both allergic and nonallergic disease. This proinflammatory effect is mediated primarily by extracellular release of IL-33 from stromal cells and binding of the C-terminal domain of IL-33 to its receptor ST2 on targets such as CD4

Indexed as

AdultAnimalsB-LymphocytesDNA ReplicationFemaleHumansInterleukin-33Leukemia, Lymphocytic, Chronic, B-CellMaleMast CellsMiceMice, Inbred BALB CMice, Inbred C57BLRNA, MessengerSignal TransductionTh2 CellsIL33 protein, humanIl33 protein, mouseInterleukin-33RNA, MessengerTumor Suppressor Protein p53

Identifiers

PMID31391233
PMCPMC6736727
OpenAlexW2966334969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.